Genmab Announces Financial Results for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 1/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
November 9, 2022 Copenhagen, Denmark;
Interim Report for the First Nine Months Ended September 30, 2022
Highlights
• Genmab revenue increased 60% compared to the first nine months of 2021, to DKK 9,368
million
• Genmab improves its 2022 financial guidance
“During the first nine months of the year we continued to build on Genmab’s consistent track record of
success. We have strengthened our pipeline, our team and our financial foundation is even more robust.
We are pleased with the recent U.S. and European regulatory submissions for epcoritamab. These
submissions are an important step in potentially bringing epcoritamab to people living with certain
hematologic malignancies who are in need of a new treatment option,” said Jan van de Winkel, Ph.D.,
Chief Executive Officer of Genmab.
Financial Performance First Nine Months of 2022
• Net sales of DARZALEX
®
by Janssen Biotech, Inc. (Janssen) were USD 5,894 million in the first
nine months of 2022 compared to USD 4,378 million in the first nine months of 2021, an increase
of USD 1,516 million, or 35%.
• Royalty revenue was DKK 8,207 million in the first nine months of 2022 compared to DKK 4,698
million in the first nine months of 2021, an increase of DKK 3,509 million, or 75%. The increase in
royalties was driven by higher net sales of DARZALEX, Kesimpta
®
and TEPEZZA
®
and a higher
average exchange rate between the USD and DKK.
• Revenue was DKK 9,368 million for the first nine months of 2022 compared to DKK 5,863 million
for the first nine months of 2021. The increase of DKK 3,505 million, or 60%, was primarily driven
by higher DARZALEX, Kesimpta and TEPEZZA royalties achieved under our collaborations with
Janssen, Novartis Pharma AG (Novartis) and Roche, respectively, an increase in Tivdak
®
collaboration revenue, and reimbursement revenue driven by higher activities under our
collaboration agreements with BioNTech SE (BioNTech), partly offset by milestones achieved
under our collaborations with Janssen and AbbVie in the first nine months of 2021.
• Operating expenses were DKK 5,676 million in the first nine months of 2022 compared to DKK
3,654 million in the first nine months of 2021. The increase of DKK 2,022 million, or 55%, was
driven by the continued advancement of epcoritamab and multiple pipeline projects, an increase
in team members to support Tivdak post launch and expansion of our product pipeline, and the
continued development of Genmab’s commercialization and broader organizational capabilities
and infrastructure.
• Operating profit was DKK 3,692 million in the first nine months of 2022 compared to DKK 2,209
million in the first nine months of 2021.
• Net financial items was income of DKK 2,681 million for the first nine months of 2022 compared
to income of DKK 808 million in the first nine months of 2021. The increase of DKK 1,873 million
was primarily driven by net foreign exchange rate gains due to the USD strengthening against the
DKK.
Genmab Announces Financial Results for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 2/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Epcoritamab Regulatory Update
There were two regulatory submissions for epcoritamab in the second half of 2022. Genmab submitted a
biologics license application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) for
subcutaneous (SC) epcoritamab for the treatment of patients with relapsed/refractory large B-cell
lymphoma (LBCL) after two or more lines of systemic therapy. Additionally, AbbVie submitted a Marketing
Authorization Application (MAA) to the European Medicines Agency (EMA) for SC epcoritamab for the
treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after two or more
lines of systemic therapy, which has been validated by the EMA. Both submissions were supported by
results from the LBCL cohort of the pivotal EPCORE™ NHL-1 open-label, multi-center trial evaluating the
safety and preliminary efficacy of epcoritamab in patients with relapsed, progressive or refractory CD20+
mature B-cell non-Hodgkin lymphoma (B-NHL), including DLBCL.
Outlook
As announced in Company Announcement No. 54, Genmab is improving its 2022 financial guidance
published on August 8, 2022, driven primarily by the positive foreign exchange rate impact on our royalty
revenue, and the continued strong performance of DARZALEX net sales.
Revised
Previous
(DKK million)
Guidance
Guidance
Revenue
13,500 - 14,500
12,000 - 13,000
Operating expenses
(8,000) - (8,400)
(7,600) - (8,200)
Operating profit
5,100 - 6,500
3,800 - 5,400
Conference Call
Genmab will hold a conference call in English to discuss the results for the first nine months of 2022
today, Wednesday, November 9, at 6:00 pm CET, 5:00 pm GMT or 12:00 pm EST. To join the call please
use the below registration link. Registered participants will receive an email with a link to access dial-in
information as well as a unique personal PIN:
https://register.vevent.com/register/BI2f752c494cf441f8b2fd8379c5219dc7
. A live and archived webcast
of the call and relevant slides will be available at www.genmab.com/investors.
Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 3/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
CONTENTS
MANAGEMENT’S REVIEW
CONSOLIDATED KEY FIGURES
4
OUTLOOK
5
KEY 2022 PRIORITIES
6
PRODUCT PIPELINE AND TECHNOLOGY PROGRESS FIRST NINE MONTHS OF 2022
7
SIGNIFICANT RISKS AND UNCERTAINTIES
15
FINANCIAL REVIEW
15
FINANCIAL STATEMENTS
22
NOTES TO THE FINANCIAL STATEMENTS
26
ABOUT GENMAB
34
DIRECTORS’ AND MANAGEMENT’S STATEMENT ON THE INTERIM REPORT
35
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 4/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
CONSOLIDATED KEY FIGURES
Three Months Ended
Nine Months Ended
September 30,
September 30,
Full Year
2022
2021
2022
2021
2021
4,087
2,310
9,368
5,863
8,482
(1,486)
(1,114)
(3,921)
(2,883)
(4,181)
(670)
(306)
(1,755)
(771)
(1,283)
(2,156)
(1,420)
(5,676)
(3,654)
(5,464)
1,931
890
3,692
2,209
3,018
1,341
281
2,681
808
965
2,582
890
4,938
2,292
3,008
13,411
10,014
13,411
10,014
10,381
10,377
8,729
10,377
8,729
8,957
1,947
2,031
1,947
2,031
1,891
30,686
23,985
30,686
23,985
24,627
26,657
21,285
26,657
21,285
22,196
66
66
66
66
66
1,968
447
3,514
1,987
2,228
(1,382)
(1,621)
(2,625)
(655)
(961)
(642)
24
(920)
(436)
(420)
(82)
(77)
(207)
(184)
(252)
39.55
13.61
75.48
35.05
46.00
39.17
13.47
74.83
34.72
45.54
2,461
2,809
2,461
2,809
2,630
6.09
8.71
6.09
8.71
7.82
403.89
322.50
403.89
322.50
336.30
87
%
89
%
87
%
89
%
90
%
65,829,282
65,685,053
65,829,282
65,685,053
65,718,456
1,516
1,089
1,402
967
1,022
1,560
1,136
1,560
1,136
1,212
* Full-time equivalent or team members
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 5/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
OUTLOOK
Revised
Previous
(DKK million)
Guidance
Guidance
Revenue
13,500 - 14,500
12,000 - 13,000
Operating expenses
(8,000) - (8,400)
(7,600) - (8,200)
Operating profit
5,100 - 6,500
3,800 - 5,400
Genmab is improving its 2022 financial guidance published on August 8, 2022, driven primarily by the
positive foreign exchange rate impact on our royalty revenue, and the continued strong performance of
DARZALEX net sales.
Revenue
Genmab expects its 2022 revenue to be in the range of DKK 13,500 – 14,500 million, an increase to the
previous guidance of DKK 12,000 – 13,000 million, driven primarily by the positive foreign exchange rate
impact on our royalty revenue, and the continued strong performance of DARZALEX net sales. Genmab’s
projected revenue for 2022 primarily consists of DARZALEX royalties of DKK 10,000 – 10,300 million
compared to the previous guidance of DKK 8,800 – 9,300 million. Such royalties are based on Genmab’s
revised estimate of DARZALEX 2022 net sales of USD 8.0 – 8.2 billion compared to the previous
guidance of USD 7.8 – 8.2 billion. DARZALEX royalties are partly offset by Genmab’s share of Janssen’s
royalty payments to Halozyme in connection with subcutaneous (SC) net sales. The upper end of the
revenue guidance range now assumes a significant milestone associated with the potential acceptance
by the U.S. FDA to review the BLA submission for epcoritamab. The remainder of Genmab’s revenue
primarily consists of royalties from TEPEZZA, Kesimpta and RYBREVANT
®
, reimbursement revenue,
milestones including those for epcoritamab and teclistamab as well as collaboration revenue with Seagen
Inc. (Seagen) for Tivdak.
Operating Expenses
Genmab anticipates its 2022 operating expenses to be in the range of DKK 8,000 – 8,400 million, an
increase to the previous guidance of DKK 7,600 – 8,200 million, primarily driven by the negative impact of
the strong U.S. Dollar. Operating expenses continue to be driven by the advancement of Genmab’s
clinical programs, continued investment in research and development, as well as building Genmab’s
commercial organization and broader organizational infrastructure.
Operating Profit
Genmab now expects its 2022 operating profit to be in the range of DKK 5,100 – 6,500 million, an
increase to the previous guidance of DKK 3,800 – 5,400 million, driven primarily by the items described
above.
Outlook: Risks and Assumptions
In addition to factors already mentioned, the estimates above are subject to change due to numerous
reasons, including but not limited to, the achievement of certain milestones associated with Genmab’s
collaboration agreements; the timing and variation of development activities (including activities carried
out by Genmab’s collaboration partners) and related income and costs; DARZALEX, Kesimpta,
TEPEZZA, RYBREVANT and TECVAYLI
®
net sales and royalties paid to Genmab; and currency
exchange rates (the 2022 guidance assumes a USD / DKK exchange rate of 7.2 compared to 6.8 in the
previous guidance). The financial guidance assumes that no significant new agreements are entered into
during the remainder of 2022 that could materially affect the results. Refer to the section “Significant
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 6/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Risks and Uncertainties” in this interim report. Additionally, depending on trends related to the
coronavirus and future variants, the COVID-19 pandemic could potentially have a material adverse
impact on Genmab’s business and financial performance, including clinical trials, projected regulatory
approval timelines, supply chain and revenues, and cause Genmab’s actual results to differ materially
from 2022 Guidance and Key 2022 Priorities in this interim report.
Should the global outbreak of COVID-19 persist, it may have long-term impacts on the development,
regulatory approval and commercialization of Genmab’s investigational medicines and on net sales of
approved medicines created by Genmab and developed and marketed by Genmab or Genmab’s
collaboration partners. As the pandemic continues, there may be an impact on Genmab’s business.
Genmab has an established COVID-19 response team, led by the CEO, that closely monitors the
evolving situation, maintains precautionary measures to help limit the impact of COVID-19 at the
workplace and on our communities, and ensures business continuity. The full extent and nature of the
impact of the COVID-19 pandemic and related containment measures on Genmab’s business and
financial performance is uncertain as the situation continues. The factors discussed above, as well as
other factors that are currently unforeseeable, may result in further and other unforeseen material
adverse impacts on Genmab’s business and financial performance, including on the sales of Tivdak and
on net sales of DARZALEX, Kesimpta, TEPEZZA, RYBREVANT and TECVAYLI by Genmab’s partners
and on Genmab’s royalty, milestone and collaboration revenue therefrom.
KEY 2022 PRIORITIES
Priority
Targeted Milestones
Broad and rapid
development of late-stage
clinical pipeline and further
build US country
organization
Epcoritamab
1
• Expand clinical development program with multiple Phase
3 trials initiated and submission of first BLA (subject to
supportive FDA feedback)
Tivdak
2
• Establish Tivdak as a clear choice for 2L+ r/m Cervical
Cancer patients
• Broaden clinical development program including Phase 2
evaluation of combination therapy in earlier line treatment
for cervical cancer and other solid tumors
Growth and development of
differentiated early-stage
product candidates
DuoBody
®
-PD-L1x4-1BB
3
& DuoBody-CD40x4-1BB
3
• Data from clinical expansion cohorts to progress to next
steps
Expand and advance proprietary clinical product portfolio
Further scale organization
aligned with growing product
portfolio and brand needs
Further scale organization aligned with differentiated antibody
product portfolio growth and future launches
Use solid financial base to grow and broaden antibody product
and technology portfolio
1. Co-development w/ AbbVie; 2. Co-development w/ Seagen; 3. Co-development w/ BioNTech
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 7/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
PRODUCT PIPELINE AND TECHNOLOGY PROGRESS FIRST NINE MONTHS OF 2022
At the end of the first nine months of 2022, Genmab’s proprietary pipeline of investigational medicines,
where we are responsible for at least 50% of development, consisted of eight antibody products in clinical
development. These include Genmab’s first U.S. FDA approved medicine, Tivdak, that Genmab is co-
developing and co-promoting in the U.S. with Seagen. In addition to our own pipeline, there are multiple
investigational medicines in development by global pharmaceutical and biotechnology companies,
including five approved medicines powered by Genmab’s technology and innovations. Beyond the
investigational medicines in clinical development, our pipeline also includes multiple preclinical programs.
An overview of the development status of each of our investigational medicines is provided in the
following sections, including updates for the third quarter of 2022. For events that occurred during the first
and second quarters of 2022, please refer to Genmab’s Q1 2022 and Q2 2022
Interim Reports,
respectively. Detailed descriptions of dosing, efficacy and safety data from certain clinical trials have been
disclosed in company announcements and media releases published via the Nasdaq Copenhagen stock
exchange and may also be found in Genmab’s filings with the U.S. Securities and Exchange Commission
(SEC). Additional information is available on Genmab’s website,
www.genmab.com. The information
accessible through our website is not part of this report and is not incorporated by reference herein.
Genmab Proprietary Investigational Medicines
1
in Development
1
Investigational medicines where Genmab has ≥50% ownership. Certain investigational medicines in co-development,
partners as indicated
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 8/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
2
See U.S. prescribing information for precise indication and safety information
3
In June 2022, AbbVie decided to discontinue co-development of DuoHexaBody-CD37. Upon expiry of the notice period,
Genmab will become solely responsible for the further development of DuoHexaBody-CD37 against low-single digit
royalty payments to AbbVie, up to an agreed maximum total royalty amount, based on future potential sales of the
product.
4
Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen
Tivdak (tisotumab vedotin-tftv) – First and only U.S. FDA approved antibody-drug conjugate (ADC)
for recurrent or metastatic cervical cancer
• An ADC directed to tissue factor (TF), a protein highly prevalent in solid tumors, including cervical
cancer, which is associated with poor prognosis
• Accelerated approval granted by the U.S. FDA for Tivdak, the first and only approved ADC for the
treatment of adult patients with recurrent or metastatic cervical cancer with disease progression
on or after chemotherapy
• U.S. FDA approval was based on data from the innovaTV 204 (NCT03438396) Phase 2 single-
arm clinical study evaluating tisotumab vedotin as monotherapy in patients with previously treated
recurrent or metastatic cervical cancer
• In addition to a Phase 3 study in recurrent or metastatic cervical cancer (innovaTV 301,
NCT04697628), multiple Phase 2 clinical studies in other solid tumors are ongoing
• Co-developed globally and co-promoted in the U.S. in collaboration with Seagen
Tivdak is an ADC composed of Genmab’s human monoclonal antibody directed to TF and Seagen’s
ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-
disrupting agent monomethyl auristatin E to the antibody. Genmab used technology licensed from
Medarex Inc. (Medarex) to generate the TF antibody forming part of Tivdak. Tivdak is the first and only
U.S. FDA approved ADC for the treatment of adult patients with recurrent or metastatic cervical cancer
with disease progression on or after chemotherapy. Tivdak is being co-developed by Genmab and
Seagen. Under a joint commercialization agreement, Genmab is co-promoting Tivdak in the U.S. and will
lead commercial operational activities in Japan. Seagen is leading commercial operational activities in
the U.S. and will lead commercial operational activities in Europe and China. In these four markets there
will be a 50:50 cost and profit split. In other markets, Seagen will commercialize Tivdak and Genmab will
receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the mid-
twenties. The companies have joint decision-making on the worldwide development and
commercialization strategy for Tivdak. The companies have a broad clinical development program for
Tivdak, including a confirmatory Phase 3 study in recurrent or metastatic cervical cancer.
Please consult the U.S. Prescribing Information
for Tivdak for the labeled indication and safety
information, including the boxed warning.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 9/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Epcoritamab (DuoBody-CD3xCD20) – Potential Best-in-class Investigational Medicine
• Bispecific antibody-based investigational medicine created with Genmab’s DuoBody technology
platform
• Multiple ongoing clinical studies across different settings and histologies, including Phase 3
studies in relapsed/refractory DLBCL (EPCORE DLBCL-1, NCT04628494) and
relapsed/refractory FL (EPCORE FL-1, NCT05409066) with more studies in planning
• In the second half of 2022 Genmab submitted a BLA to the U.S. FDA for SC epcoritamab for the
treatment of patients with relapsed/refractory LBCL and AbbVie submitted an MAA to the EMA for
SC epcoritamab for the treatment of patients with relapsed/refractory DLBCL. The submissions
were supported by results from the LBCL cohort of the pivotal EPCORE NHL-1 open-label, multi-
center trial evaluating the safety and preliminary efficacy of epcoritamab in patients with relapsed,
progressive or refractory CD20+ mature B-NHL, including DLBCL.
• Co-developed in collaboration with AbbVie
Epcoritamab is a proprietary bispecific antibody created using Genmab’s DuoBody technology platform.
Epcoritamab targets CD3, which is expressed on T-cells, and CD20, a clinically well-validated target on
malignant B-cells. Genmab used technology licensed from Medarex to generate the CD20 antibody
forming part of epcoritamab. Epcoritamab is being co-developed by Genmab and AbbVie. The companies
have a broad clinical development program for epcoritamab including two ongoing Phase 3 studies with
multiple others in planning. The combination of epcoritamab and DuoHexaBody-CD37 (GEN3009) is also
being explored in an arm of a Phase 1/2 clinical study (NCT04358458) of DuoHexaBody-CD37 in
hematologic malignancies.
Third Quarter 2022 Updates
• H2 2022: As noted above, Genmab and AbbVie respectively submitted applications for approval
to U.S. and EU regulatory authorities for epcoritamab in certain hematologic malignancies.
• July: Genmab announced AbbVie’s intent to submit a conditional MAA to the EMA for SC
epcoritamab for the treatment of patients with relapsed/refractory DLBCL in the second half of
2022.
DuoBody-PD-L1x4-1BB (GEN1046/BNT311) – Bispecific Next Generation Checkpoint
Immunotherapy
• Bispecific antibody-based investigational medicine created with Genmab’s DuoBody technology
platform
• Clinical studies in solid tumors ongoing, including a Phase 2 study in non-small cell lung cancer
(NSCLC) (NCT05117242)
• Co-developed in collaboration with BioNTech
DuoBody-PD-L1x4-1BB is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech,
created using Genmab’s DuoBody technology platform. It is being co-developed by Genmab and
BioNTech under an agreement in which the companies share all costs and future potential profits for
DuoBody-PD-L1x4-1BB on a 50:50 basis. DuoBody-PD-L1x4-1BB is designed to induce an antitumor
immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB
stimulation using an inert DuoBody format. Three clinical studies in solid tumors are ongoing including a
Phase 2 study of DuoBody-PD-L1x4-1BB as monotherapy or in combination with pembrolizumab in
patients with recurrent metastatic NSCLC.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 10/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
DuoBody-CD40x4-1BB (GEN1042/BNT312) – Potential First-in-Class Bispecific Agonistic Antibody
• Bispecific antibody-based investigational medicine created with Genmab’s DuoBody technology
platform
• Phase 1/2 clinical study in solid tumors ongoing (NCT04083599)
• Co-developed in collaboration with BioNTech
DuoBody-CD40x4-1BB is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech,
created using Genmab’s DuoBody technology platform. It is being co-developed by Genmab and
BioNTech under an agreement in which the companies share all costs and future potential profits for
DuoBody-CD40x4-1BB on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both
dendritic cells and antigen-dependent T-cell activation, using an inert DuoBody format. A Phase 1/2
clinical study of DuoBody-CD40x4-1BB in solid tumors is ongoing.
HexaBody-CD27 (GEN1053/BNT313) – First-in-Human Study Recruiting
• Investigational medicine created with Genmab’s HexaBody technology platform
• Phase 1/2 clinical study in solid tumors recruiting (NCT05435339)
• Co-developed in collaboration with BioNTech
HexaBody-CD27 is a CD27 antibody that utilizes Genmab’s HexaBody technology, specifically
engineered to form an antibody hexamer (a formation of six antibodies) upon binding its target on the cell
membrane of the T cells. It is being co-developed by Genmab and BioNTech under an agreement in
which the companies share all costs and future potential profits for HexaBody-CD27 on a 50:50 basis. A
Phase 1/2 clinical study of HexaBody-CD27 in solid tumors is recruiting.
DuoHexaBody-CD37 (GEN3009) – First DuoHexaBody Program in the Clinic
• Antibody-based investigational medicine created with Genmab’s DuoHexaBody technology
platform
• Phase 1/2 clinical study in hematologic malignancies ongoing (NCT04358458)
DuoHexaBody-CD37 is a bispecific antibody that targets two non-overlapping CD37 epitopes, created
using Genmab’s DuoHexaBody technology platform. The DuoHexaBody technology platform combines
the dual targeting of our DuoBody technology platform with the enhanced potency of our HexaBody
technology platform, creating bispecific antibodies with target-mediated enhanced hexamerization. In
June 2022 AbbVie decided to discontinue co-development of DuoHexaBody-CD37. Upon expiry of the
notice period, Genmab will become solely responsible for the further development of DuoHexaBody-
CD37 against low-single digit royalty payments to AbbVie, up to an agreed maximum total royalty
amount, based on future potential sales of the product. A Phase 1/2 clinical study in hematologic
malignancies, including an arm in combination with epcoritamab, is ongoing.
HexaBody-CD38 (GEN3014) – HexaBody Molecule with Potential in Hematological Malignancies
• Antibody-based investigational medicine created with Genmab’s HexaBody technology platform
• Phase 1/2 clinical study in hematological malignancies ongoing (NCT04824794)
• Developed in an exclusive worldwide license and option agreement with Janssen
HexaBody-CD38 is a human CD38 monoclonal antibody-based investigational medicine created using
Genmab’s HexaBody technology platform. In preclinical models of hematological malignancies
HexaBody-CD38 demonstrated highly potent complement-dependent cytotoxicity and showed potent anti-
tumor activity. In June 2019, Genmab entered into an exclusive worldwide license and option agreement
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 11/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
with Janssen to develop and commercialize HexaBody-CD38. A Phase 1/2 clinical study in hematologic
malignancies is ongoing.
DuoBody-CD3xB7H4 (GEN1047) – Bispecific with Potential in Solid Tumors
• Bispecific antibody-based investigational medicine created with Genmab’s DuoBody technology
platform
• Phase 1/2 clinical study in malignant solid tumors ongoing (NCT05180474)
DuoBody-CD3xB7H4 is a bispecific antibody-based investigational medicine created using Genmab’s
DuoBody technology platform. B7H4 is an immune checkpoint protein expressed on malignant cells in
various solid cancers including breast, ovarian and lung cancer. In preclinical studies, DuoBody-
CD3xB7H4 induced T-cell mediated cytotoxicity of B7H4-positive tumor cells. DuoBody-CD3xB7H4 is
being developed for the potential treatment of solid cancer indications known to express B7H4. A Phase
1/2 clinical study of DuoBody-CD3xB7H4 in malignant solid tumors is ongoing.
Products Powered by Genmab’s Technology and Innovations
In addition to Genmab’s own pipeline of investigational medicines, our innovations and proprietary
technology platforms are applied in the pipelines of global pharmaceutical and biotechnology companies.
These companies are running clinical development programs with antibodies created by Genmab or
created using Genmab’s proprietary DuoBody bispecific antibody technology platform. The programs run
from Phase 1 development to approved medicines. The tables in this section include those therapies that
have been approved in certain territories as well as clinical stage investigational medicines in Phase 2
development or later. Under the agreements for these products Genmab is entitled to certain potential
milestones and royalties.
Approved Medicines
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 12/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
*
See local country prescribing information for precise indications and safety information
DARZALEX (daratumumab) – Redefining the Treatment of Multiple Myeloma
• First-in-class human CD38 monoclonal antibody
• Developed and commercialized by Janssen under an exclusive worldwide license from Genmab
• Intravenous (IV) product approved in combination with other therapies for frontline and for
relapsed/refractory multiple myeloma in territories including the U.S., Europe and Japan and as
monotherapy for heavily pretreated or double-refractory multiple myeloma in territories including
the U.S. and Europe
• First and only SC CD38-directed antibody approved in territories including the U.S., Europe and
Japan for the treatment of certain multiple myeloma indications, known as DARZALEX FASPRO
®
(daratumumab and hyaluronidase-fihj) in the U.S., and DARZALEX SC in Europe
• SC daratumumab is the first and only approved therapy for light-chain (AL) amyloidosis in the
U.S., Europe and Japan
• Net sales of DARZALEX by Janssen were USD 5,894 million in the first nine months of 2022
DARZALEX is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is
highly expressed on the surface of multiple myeloma cells and is also expressed by AL amyloidosis
plasma cells. Genmab used technology licensed from Medarex to generate the CD38 antibody forming
part of daratumumab. Daratumumab is being developed by Janssen under an exclusive worldwide
license from Genmab to develop, manufacture and commercialize daratumumab. Under the terms of the
agreement, Genmab is entitled to double digit royalties between 12% and 20% with Janssen reducing
such royalty payments for Genmab’s share of Janssen’s royalty payments made to Halozyme
Therapeutics, Inc. (Halozyme). Daratumumab (marketed as DARZALEX for IV administration and as
DARZALEX FASPRO in the United States and as DARZALEX SC in Europe for SC administration) is
approved in a large number of territories for the treatment of adult patients with certain multiple myeloma
indications and is the only approved therapy in the U.S., Europe and Japan for the treatment of adult
patients with AL amyloidosis.
Please consult the European Summary of Product Characteristics
for DARZALEX and DARZALEX SC
and the U.S. Prescribing Information for DARZALEX and DARZALEX FASPRO for the labeled indication
and safety information.
Kesimpta (ofatumumab) – Approved in treatment of relapsing forms of multiple sclerosis (RMS)
• Human CD20 monoclonal antibody developed and commercialized by Novartis under a license
agreement with Genmab
• Approved in territories including the U.S., EU and Japan for the treatment of RMS in adults
• First B-cell therapy that can be self-administered by patients at home using the Sensoready
®
autoinjector pen
Kesimpta is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing
parts of the small and large extracellular loops. Genmab used technology licensed from Medarex to
generate the CD20 antibody forming part of Kesimpta. Kesimpta is approved in territories including the
U.S., Europe and Japan for the treatment of certain adult patients with RMS. Kesimpta is the first B-cell
therapy that can be self-administered by patients at home using the Sensoready autoinjector pen, once
monthly after starting therapy. Kesimpta is being developed and marketed worldwide by Novartis under a
license agreement between Genmab and Novartis. Under the terms of the agreement, Genmab is entitled
to 10% royalties on net sales of Kesimpta.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 13/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Please consult the U.S. Prescribing Information and the European Summary of Product Characteristics
for the labeled indication and safety information for Kesimpta.
TEPEZZA (teprotumumab-trbw) – First U.S. FDA-approved medicine for the treatment of thyroid
eye disease (TED)
• Developed and commercialized by Horizon Therapeutics, plc (Horizon) for the treatment of TED
• First and only U.S. FDA-approved medicine for the treatment of TED
• Also being explored in a clinical trial for the treatment of diffuse cutaneous systemic sclerosis
(dcSSC)
Teprotumumab, approved by the U.S. FDA under the trade name TEPEZZA, is a human monoclonal
antibody that targets the Insulin-like Growth Factor 1 Receptor (IGF-1R), a well-validated target. Genmab
used technology licensed from Medarex to generate the IGF-1R antibody forming part of teprotumumab.
The antibody was created by Genmab under a collaboration with Roche and development and
commercialization of the product is now being conducted by Horizon under a sublicense from Roche.
Under the terms of Genmab’s agreement with Roche, Genmab will receive mid-single digit royalties on
net sales of TEPEZZA.
Please consult the U.S. Prescribing Information
for the labeled indication and safety information for
TEPEZZA.
RYBREVANT (amivantamab-vmjw) – First regulatory approvals for a DuoBody-based Medicine
• Part of Genmab and Janssen DuoBody research and license agreement
• First approved medicine created using Genmab’s proprietary DuoBody technology platform
• Under the agreement with Janssen, Genmab will receive milestones and royalties on net sales of
RYBREVANT
In July 2012, Genmab entered into a collaboration with Janssen to create and develop bispecific
antibodies using Genmab’s DuoBody technology platform. One of these, Janssen’s
RYBREVANT, is a fully human bispecific antibody that targets epidermal growth factor receptor
(EGFR) and Met, two validated cancer targets. The two antibody libraries used to produce
amivantamab were both generated by Genmab. In collaboration with Janssen, the antibody pair
used to create amivantamab was selected. Janssen is responsible for the development and
commercialization of amivantamab.
In 2021, Janssen received approvals in the U.S., Europe and other markets for RYBREVANT for
the treatment of certain adult patients with NSCLC with EGFR exon 20 insertion mutations. These
were the first regulatory approvals for a therapy that was created using Genmab’s proprietary
DuoBody bispecific technology platform. Under our agreement with Janssen, Genmab will receive
milestones and royalties between 8% and 10% on net sales of RYBREVANT.
Please consult the U.S. Prescribing Information and the
European Summary of Product
Characteristics for RYBREVANT for the labeled indication and safety information.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 14/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
TECVAYLI (teclistamab) – Approved in Europe for the treatment of relapsed and refractory
multiple myeloma
• Part of Genmab and Janssen DuoBody research and license agreement
• Second approved medicine created using Genmab’s proprietary DuoBody technology platform
• Under the agreement with Janssen, Genmab will receive milestones and royalties on net sales of
TECVAYLI
In July 2012, Genmab entered into a collaboration with Janssen to create and develop bispecific
antibodies using Genmab’s DuoBody technology platform. One of the products subsequently created,
discovered and developed by Janssen is TECVAYLI, a bispecific antibody that targets CD3, which is
expressed on T-cells and B-cell maturation antigen (BCMA), which is expressed in mature B
lymphocytes.
In August 2022, Janssen received conditional marketing authorization from the European Commission for
subcutaneously administered TECVAYLI as monotherapy for the treatment of adult patients with relapsed
and refractory multiple myeloma. Patients must have received at least three prior therapies, including an
immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated
disease progression on the last therapy. TECVAYLI is the second therapy created using Genmab’s
proprietary DuoBody bispecific technology platform to receive regulatory approval. Under our agreement
with Janssen, Genmab will receive milestones and mid-single digit royalties on net sales of TECVAYLI.
Please consult the European Summary of Product Characteristics
for TECVAYLI for the labeled indication
and safety information.
Clinical Stage Investigational Medicines, >Phase 2 Development
*
UltiMAb
transgenic mouse technology licensed from Medarex, a wholly owned subsidiary of Bristol Myers Squibb.
Preclinical Programs
• Broad preclinical pipeline that includes both partnered products and in-house programs based on
our proprietary technologies or antibodies
• Multiple new Investigational New Drug (IND) applications expected to be submitted over coming
years
• Genmab has entered multiple strategic collaborations to support the expansion of our innovative
pipeline
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 15/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Our preclinical pipeline includes immune effector function enhanced antibodies developed with our
HexaBody technology platform and bispecific antibodies created with our DuoBody technology platform.
We are also working with our partners to generate additional new antibody-based product concepts. A
number of the preclinical programs are carried out in cooperation with our collaboration partners.
Third Quarter 2022 Updates
• August: Genmab and BioNTech expanded the companies’ global strategic collaboration to
develop and commercialize novel immunotherapies for the treatment of cancer patients. Under
the expansion, the companies will jointly develop and commercialize, subject to regulatory
approval, monospecific antibodies leveraging Genmab’s proprietary HexaBody technology
platform. The first monospecific antibody candidate under the collaboration is HexaBody-CD27.
• July: The first Clinical Trial Application (CTA) was submitted for GEN1056/BNT322.
GEN1056/BNT322 is an antibody product being co-developed by Genmab and BioNTech for the
treatment of solid tumors and for use in combination with other products.
SIGNIFICANT RISKS AND UNCERTAINTIES
As a biotech company, Genmab faces a number of risks and uncertainties. These are common for the
industry and relate to operations, intellectual property, research and development, commercialization and
financial activities. For further information about risks and uncertainties which Genmab faces, refer to the
2021 Annual Report filed with NASDAQ Copenhagen and the Form 20-F filed with the U.S. SEC, both of
which were filed in February 2022. At the date of this interim report, there have been no significant
changes to Genmab’s overall risk profile since the publication of these reports; however, the full extent
and nature of the impact of the COVID-19 pandemic and related containment measures on our business
and financial performance is uncertain. See Genmab’s Form 20-F for a detailed summary of risks related
to our collaborations as well as risks related to the COVID-19 pandemic.
FINANCIAL REVIEW
The interim report is prepared on a consolidated basis for the Genmab group. The financial statements
are published in Danish Kroner (DKK).
Revenue
Genmab’s revenue was DKK 9,368 million for the first nine months of 2022 compared to DKK 5,863
million for the first nine months of 2021. The increase of DKK 3,505 million, or 60%, was primarily driven
by higher DARZALEX, Kesimpta and TEPEZZA royalties achieved under our collaborations with Janssen,
Novartis and Roche, respectively, an increase in TIVDAK collaboration revenue, and reimbursement
revenue driven by higher activities under our collaboration agreements with BioNTech, partly offset by
milestones achieved under our collaborations with Janssen and AbbVie in the first nine months of 2021.
Three Months Ended
Nine Months Ended
September 30,
September 30,
(DKK million)
2022
2021
2022
2021
Royalties
3,480
2,103
8,207
4,698
Reimbursement revenue
307
144
594
371
Milestone revenue
112
63
288
794
Collaboration revenue
182
—
273
—
License revenue
6
—
6
—
Total revenue
4,087
2,310
9,368
5,863
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 16/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Royalties
Royalty revenue amounted to DKK 8,207 million in the first nine months of 2022 compared to DKK 4,698
million in the first nine months of 2021. The increase of DKK 3,509 million, or 75%, was primarily driven
by higher DARZALEX, Kesimpta and TEPEZZA royalties achieved under our daratumumab collaboration
with Janssen, ofatumumab collaboration with Novartis, and teprotumumab collaboration with Roche,
respectively. The table below summarizes Genmab’s royalty revenue by product.
Three Months Ended
Nine Months Ended
September 30,
September 30,
(DKK million)
2022
2021
2022
2021
DARZALEX
3,049
1,807
7,073
4,167
TEPEZZA
207
222
597
384
Kesimpta
213
68
509
140
Other
11
6
28
7
Total royalties
3,480
2,103
8,207
4,698
Net sales of DARZALEX by Janssen were USD 5,894 million in the first nine months of 2022 compared to
USD 4,378 million in the first nine months of 2021. The increase of USD 1,516 million, or 35%, was driven
by share gains, continued strong market growth and uptake of the DARZALEX SC product. Royalty
revenue on net sales of DARZALEX
was DKK 7,073 million in the first nine months of 2022 compared to
DKK 4,167 million in the first nine months of 2021, an increase of DKK 2,906 million. The percentage
increase in royalties of 70% is higher than the percentage increase in the underlying net sales primarily
due to the higher average exchange rate between the USD and DKK, other positive foreign exchange
rate impacts, and a higher effective royalty rate for the first nine months of 2022, partly offset by the
increase in Genmab’s share of Janssen’s royalty payments to Halozyme in connection with SC product
net sales. Under our license agreement with Janssen for DARZALEX, for purposes of calculating royalties
due to Genmab, DARZALEX net sales for non-U.S. dollar denominated currencies are translated to U.S.
dollars at a specified annual Currency Hedge Rate. This contractual arrangement is the driver for the
other foreign exchange impacts discussed above.
Net sales of TEPEZZA by Horizon were USD 1,472 million in the first nine months of 2022 compared to
USD 1,072 million in the first nine months of 2021. TEPEZZA net sales in the first quarter of 2021 were
negatively impacted by the U.S. government-mandated COVID-19 production interruption. Royalty
revenue on net sales of TEPEZZA was DKK 597 million in the first nine months of 2022 compared to DKK
384 million in the first nine months of 2021, an increase of DKK 213 million, or 55%.
Net sales of Kesimpta by Novartis were USD 723 million in the first nine months of 2022 compared to
USD 224 million in the first nine months of 2021. The increase of USD 499 million was primarily driven by
US launch momentum. Royalty revenue on net sales of Kesimpta was DKK 509 million in the first nine
months of 2022 compared to DKK 140 million in the first nine months of 2021, an increase of DKK 369
million.
Janssen was granted U.S. FDA approval for RYBREVANT during the second quarter of 2021, and
Genmab subsequently started recognizing royalties on net sales of RYBREVANT. Royalties were not
material for the first nine months of 2022 or 2021.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 17/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Royalty revenue fluctuations from period to period are due primarily to the level of product net sales,
foreign currency exchange rates and more specifically to DARZALEX, Genmab’s share of Janssen’s
royalty payments to Halozyme in connection with SC product net sales.
Reimbursement Revenue
Reimbursement revenue amounted to DKK 594 million in the first nine months of 2022 compared to DKK
371 million in the first nine months of 2021. The increase of DKK 223 million, or 60%, was primarily driven
by higher activities under our collaboration agreements with BioNTech for HexaBody-CD27 and
DuoBody-CD40x4-1BB.
Milestone Revenue
Milestone revenue was DKK 288 million in the first nine months of 2022 compared to DKK 794 million in
the first nine months of 2021, a decrease of DKK 506 million, or 64%, primarily driven by milestones
achieved in the first nine months of 2021 under our Janssen and AbbVie collaborations.
Milestone revenue may fluctuate significantly from period to period due to both the timing of
achievements and the varying amount of each individual milestone under our license and collaboration
agreements.
Collaboration Revenue
In September 2021, Genmab and Seagen announced U.S. FDA accelerated approval for Tivdak in
previously treated recurrent or metastatic cervical cancer. Collaboration revenue was DKK 273 million for
the first nine months of 2022 and includes a one-off payment due from Seagen of approximately USD 15
million (DKK 112 million) which reflects Genmab’s share (50%) of payments received by Seagen in
connection with the sublicense of its rights to develop and commercialize tisotumab vedotin in China to
Zai Lab Hong Kong pursuant to Genmab’s Joint Commercialization Agreement with Seagen.
Refer to Financial Statement Note 2 in this interim report for further details about revenue.
Key Developments to Revenue - Third Quarter of 2022
Genmab’s revenue was DKK 4,087 million for the third quarter of 2022 compared to DKK 2,310 million for
the third quarter of 2021. The increase of DKK 1,777 million, or 77%, was primarily driven by higher
DARZALEX royalties achieved under our collaboration with Janssen.
Janssen was granted approval for TECVAYLI in Europe for the treatment of relapsed and refractory
multiple myeloma during the third quarter of 2022. Milestone revenue in the third quarter of 2022 includes
a USD 15 million (DKK 112 million) milestone due from Janssen for the approval of TECVAYLI in Europe
for the treatment of relapsed and refractory multiple myeloma.
Collaboration revenue in the third quarter of 2022 includes a one-off payment due from Seagen as
described above.
Research and Development Expenses
Research and development expenses amounted to DKK 3,921 million in the first nine months of 2022
compared to DKK 2,883 million in the first nine months of 2021. The increase of DKK 1,038 million, or
36%, was driven by the continued advancement of epcoritamab under our collaboration with AbbVie,
continued advancement of DuoBody-CD40x4-1BB under our collaboration with BioNTech, and the
increase in team members to support the expansion of our product pipeline.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 18/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Research and development expenses accounted for 69% of total operating expenses in the first nine
months of 2022 compared to 79% in the first nine months of 2021.
Key Developments to Research and Development Expenses - Third Quarter of 2022
During the third quarter of 2022, Genmab recognized research and development expenses related to an
upfront payment of USD 10 million related to its licensing agreement with Oxford BioTherapeutics (OBT).
The amount is included in Other payables – current on the Balance Sheet as of September 30, 2022.
No significant key developments other than the item described above.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were DKK 1,755 million in the first nine months of 2022
compared to DKK 771 million in the first nine months of 2021. The increase of DKK 984 million, or 128%,
was driven by the increase in team members to support Tivdak post launch, continued expansion of
Genmab’s commercialization capabilities in support of future launches, and investment in broader
organizational infrastructure, including our technology portfolio.
Selling, general and administrative expenses accounted for 31% of total operating expenses in the first
nine months of 2022 compared to 21% in the first nine months of 2021.
Key Developments to Selling, General, and Administrative Expenses - Third Quarter of 2022
No significant key developments other than the items described above.
Operating Profit
Operating profit was DKK 3,692 million in the first nine months of 2022 compared to DKK 2,209 million in
the first nine months of 2021. Operating profit was DKK 1,931 million in the third quarter of 2022
compared to DKK 890 million in the third quarter of 2021.
Net Financial Items
Net financial items were comprised of the following:
Three Months Ended
Nine Months Ended
September 30,
September 30,
(DKK million)
2022
2021
2022
2021
Interest and other financial income
97
35
184
162
Foreign exchange rate gain, net
1,456
476
3,248
1,049
Total financial income
1,553
511
3,432
1,211
Interest and other financial expenses
(6)
(4)
(16)
(10)
Loss on marketable securities, net
(140)
(50)
(455)
(184)
Loss on other investments, net
(66)
(176)
(280)
(209)
Total financial expenses
(212)
(230)
(751)
(403)
Net financial items
1,341
281
2,681
808
Net financial items increased by DKK 1,873 million for the first nine months of 2022, primarily driven by:
• Increase in foreign exchange rate gain, net due to the USD strengthening against the DKK which
was more favorable to our marketable securities, and cash and cash equivalents in the first nine
months of 2022,
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 19/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
• Loss on marketable securities driven by increases in interest rates in the United States and
Europe, and
• Loss on other investments due primarily to the decrease in fair value of Genmab’s investments in
common shares of CureVac.
Refer to Financial Statement Note 4 in this interim report for further details about the net financial items.
Key Developments to Net Financial Items - Third Quarter of 2022
No significant key developments other than the items described above.
Corporate Tax
Corporate tax expense for the first nine months of 2022 was DKK 1,435 million compared to DKK 725
million for the first nine months of 2021. The increase in corporate tax expense is primarily the result of
Genmab’s higher net profit before tax. The effective tax rate in the first nine months of 2022 was 22.5%
compared to 24% in the first nine months of 2021. The decrease in Genmab’s effective tax rate was
driven by the geographical composition of pre-tax profit in the first nine months of 2022 as compared to
the first nine months of 2021.
Key Developments to Corporate Tax - Third Quarter of 2022
No significant key developments other than the items described above.
Net Profit
Net profit for the first nine months of 2022 was DKK 4,938 million compared to DKK 2,292 million in the
first nine months of 2021. Net profit for the third quarter of 2022 was DKK 2,582 million compared to DKK
890 million in the third quarter of 2021. The increases in the respective periods were driven by the items
described above.
Liquidity and Capital Resources
(DKK million)
September 30, 2022
December 31, 2021
Marketable securities
13,411
10,381
Cash and cash equivalents
10,377
8,957
Shareholders' equity
26,657
22,196
Three Months Ended
Nine Months Ended
September 30,
September 30,
Cash Flow (DKK million)
2022
2021
2022
2021
Cash provided by operating activities
1,968
447
3,514
1,987
Cash (used in) investing activities
(1,382)
(1,621)
(2,625)
(655)
Cash (used in) / provided by financing activities
(642)
24
(920)
(436)
Exchange rate adjustments
617
402
1,451
573
Net cash provided by operating activities is primarily related to our operating profit, changes in operating
assets and liabilities, reversal of net financial items, and adjustments related to non-cash transactions.
Cash provided by operating activities increased compared to the first nine months of 2021 primarily driven
by an increase in operating profit of DKK 1,483 million, partly offset by the timing of corporate tax
payments of DKK 455 million in Denmark in the first nine months of 2022.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 20/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Net cash (used in) investing activities primarily reflects differences between the proceeds received from
the sale and maturity of our investments and amounts invested, and the cash paid for investments in
tangible assets. Purchases of marketable securities exceeded sales and maturities to a greater extent in
the first nine months of 2022 compared to the first nine months of 2021. For the first nine months of 2021,
investing activities also include the proceeds from the sale of CureVac shares of DKK 438 million. There
were no sales of other investments in the first nine months of 2022.
Net cash (used in) / provided by financing activities is primarily related to the purchase of treasury shares,
exercise of warrants, lease payments, and payment of withholding taxes on behalf of employees on net
settled Restricted Stock Units (RSUs). The increase in cash used in financing activities for the periods is
primarily driven by cash payments for the purchase of treasury shares of DKK 908 million in the first nine
months of 2022 compared to DKK 447 million in the first nine months of 2021.
Exchange rate adjustments represent foreign currency gains or losses on Genmab’s cash and cash
equivalents, primarily driven by our cash and cash equivalents holdings denominated in USD. The
increase in exchange rate adjustments results from the USD strengthening against the DKK to a much
greater extent in the first nine months of 2022 compared to the first nine months of 2021.
Genmab’s USD denominated cash and cash equivalents, and marketable securities represented 89% of
Genmab’s total cash and cash equivalents, and marketable securities as of September 30, 2022
compared to 86% as of December 31, 2021.
Cash and cash equivalents included short-term marketable securities of DKK 1,295 million as of
September 30, 2022 compared to DKK 296 million as of December 31, 2021. In accordance with our
accounting policy, securities purchased with a maturity of less than ninety days at the date of acquisition
are classified as cash and cash equivalents. Refer to Financial Statement Note 3 in this interim report for
further details about our marketable securities.
Key Developments to Cash Flows - Third Quarter of 2022
No significant key developments other than the items described above.
Balance Sheet
As of September 30, 2022, total assets were DKK 30,686 million compared to DKK 24,627 million on
December 31, 2021. As of September 30, 2022, assets were mainly comprised of marketable securities
of DKK 13,411 million, cash and cash equivalents of DKK 10,377 million and current receivables of DKK
4,951 million. The current receivables consist primarily of amounts related to royalties from our
collaboration agreements.
As of September 30, 2022, total liabilities were DKK 4,029 million compared to DKK 2,431 million on
December 31, 2021. The increase in total liabilities of DKK 1,598 million, or 66%, was primarily driven by
the increase in corporate tax payable due to Genmab’s net result before tax and timing of estimated tax
payments, and increase in accrued research and development costs related to the continued
advancement of Genmab projects.
Shareholders’ equity as of September 30, 2022 was DKK 26,657 million compared to DKK 22,196 million
on December 31, 2021. The increase of DKK 4,461 million, or 20%, was driven primarily by Genmab’s
net profit and share-based compensation expense related to the issuance of shares under Genmab’s
warrant and RSU programs, partly offset by the purchase of treasury shares during the period. Genmab’s
equity ratio was 87% as of September 30, 2022 compared to 90% as of December 31, 2021.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 21/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Team Members
As of September 30, 2022, the total number of team members was 1,560 compared to 1,136 as of
September 30, 2021. The increase was primarily driven by the expansion and acceleration of our
pipeline, as well as the investment in the expansion of Genmab’s commercialization capabilities, including
support for Tivdak post launch and future launches, and broader organizational infrastructure.
Team Members
September 30, 2022
September 30, 2021
Research and development team members
1,129
871
Selling, general and administrative team members
431
265
Total team members
1,560
1,136
Legal Matters – Janssen Binding Arbitrations
In September 2020, Genmab commenced binding arbitration of two matters arising under its license
agreement with Janssen relating to daratumumab. Under the license agreement, Genmab is, among
other things, entitled to royalties from Janssen on net sales of daratumumab (marketed as DARZALEX for
IV administration and as DARZALEX FASPRO in the United States and as DARZALEX SC in Europe for
SC administration). In April 2022, the arbitral tribunal issued an award in the binding arbitration of the two
matters. Genmab did not seek a review of the award, and the award is now final.
On June 9, 2022, Genmab announced the commencement of a second arbitration under the
daratumumab license agreement with Janssen. This second arbitration follows from the award in the prior
arbitration, where the tribunal ruled in favor of Janssen on the question as to whether Genmab is required
to share in Janssen’s royalty payments to Halozyme for its technology used in the daratumumab SC
product. The tribunal based its ruling on the finding that DARZALEX FASPRO constitutes a new licensed
product under the license agreement.
In this second arbitration, Genmab is consequently seeking an award of USD 405 million plus interest in
accrued milestone payments for DARZALEX FASPRO and a declaration that it is entitled to a new 13-
year royalty term from the date of DARZALEX FASPRO’s first commercial sale. See Company
Announcement no. 21.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 22/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
STATEMENTS OF COMPREHENSIVE INCOME
Income Statement
Three Months Ended
Nine Months Ended
September 30,
September 30,
Note
2022
2021
2022
2021
(DKK million)
Revenue
2
4,087
2,310
9,368
5,863
Research and development expenses
(1,486)
(1,114)
(3,921)
(2,883)
Selling, general and administrative expenses
(670)
(306)
(1,755)
(771)
Operating expenses
(2,156)
(1,420)
(5,676)
(3,654)
Operating profit
1,931
890
3,692
2,209
Financial income
4
1,553
511
3,432
1,211
Financial expenses
4
(212)
(230)
(751)
(403)
Net profit before tax
3,272
1,171
6,373
3,017
Corporate tax
(690)
(281)
(1,435)
(725)
Net profit
2,582
890
4,938
2,292
Basic net profit per share
39.55
13.61
75.48
35.05
Diluted net profit per share
39.17
13.47
74.83
34.72
Statement of Comprehensive Income
Net profit
2,582
890
4,938
2,292
Other comprehensive income:
Amounts which will be re-classified to the
income statement:
Adjustment of foreign currency fluctuations on
subsidiaries
41
2
70
30
Total comprehensive income
2,623
892
5,008
2,322
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 23/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
BALANCE SHEETS
September 30,
December 31,
Note
2022
2021
(DKK million)
ASSETS
Intangible assets
200
254
Property and equipment
741
621
Right-of-use assets
7
548
354
Receivables
39
27
Deferred tax assets
264
264
Other investments
3
155
371
Total non-current assets
1,947
1,891
Corporate tax receivable
—
31
Receivables
4,951
3,367
Marketable securities
3
13,411
10,381
Cash and cash equivalents
10,377
8,957
Total current assets
28,739
22,736
Total assets
30,686
24,627
SHAREHOLDERS’ EQUITY AND LIABILITIES
Share capital
66
66
Share premium
12,141
12,029
Other reserves
151
81
Retained earnings
14,299
10,020
Total shareholders' equity
26,657
22,196
Provisions
7
13
Lease liabilities
7
550
363
Deferred revenue
2
480
487
Other payables
4
—
Total non-current liabilities
1,041
863
Provisions
6
—
Corporate tax payable
948
—
Lease liabilities
7
79
62
Deferred revenue
2
33
26
Other payables
1,922
1,480
Total current liabilities
2,988
1,568
Total liabilities
4,029
2,431
Total shareholders' equity and liabilities
30,686
24,627
Share-based instruments
5
Related parties
6
Subsequent events to the balance sheet date
8
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 24/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
STATEMENTS OF CASH FLOWS
Nine Months Ended
September 30,
Note
2022
2021
(DKK million)
Net profit before tax
6,373
3,017
Reversal of financial items, net
(2,681)
(808)
Adjustments for non-cash transactions
574
376
Changes in operating assets and liabilities
(454)
(756)
Cash flows from operating activities before
financial items
3,812
1,829
Interest received
169
169
Interest elements of lease payments
7
(11)
(9)
Interest paid
(1)
—
Corporate taxes paid
(455)
(2)
Net cash provided by operating activities
3,514
1,987
Investment in tangible assets
(207)
(184)
Marketable securities bought
(7,238)
(13,529)
Marketable securities sold
4,850
12,712
Other investments bought
(30)
(92)
Other investments sold
—
438
Net cash (used in) investing activities
(2,625)
(655)
Warrants exercised
112
102
Principal elements of lease payments
(47)
(50)
Purchase of treasury shares
5
(908)
(447)
Payment of withholding taxes on behalf of employees
on net settled RSUs
(77)
(41)
Net cash (used in) financing activities
(920)
(436)
Change in cash and cash equivalents
(31)
896
Cash and cash equivalents at the beginning of the
period
8,957
7,260
Exchange rate adjustments
1,451
573
Cash and cash equivalents at the end of the
period
10,377
8,729
Cash and cash equivalents include:
Bank deposits
9,082
8,542
Short-term marketable securities
1,295
187
Cash and cash equivalents at the end of the
period
10,377
8,729
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 25/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
STATEMENTS OF CHANGES IN EQUITY
Share
Share
Translation
Retained
Shareholders'
capital
premium
reserves
earnings
equity
(DKK million)
Balance at December 31, 2020
66
11,894
54
7,107
19,121
Net profit
—
—
—
2,292
2,292
Other comprehensive income
—
—
30
—
30
Total comprehensive income
—
—
30
2,292
2,322
Transactions with owners:
Exercise of warrants
—
102
—
—
102
Purchase of treasury shares
—
—
—
(447)
(447)
Share-based compensation expenses
—
—
—
228
228
Net settlement of RSUs
—
—
—
(41)
(41)
Balance at September 30, 2021
66
11,996
84
9,139
21,285
Balance at December 31, 2021
66
12,029
81
10,020
22,196
Net profit
—
—
—
4,938
4,938
Other comprehensive income
—
—
70
—
70
Total comprehensive income
—
—
70
4,938
5,008
Transactions with owners:
Exercise of warrants
—
112
—
—
112
Purchase of treasury shares
—
—
—
(908)
(908)
Share-based compensation expenses
—
—
—
326
326
Net settlement of RSUs
—
—
—
(77)
(77)
Balance at September 30, 2022
66
12,141
151
14,299
26,657
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 26/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
NOTES TO THE FINANCIAL STATEMENTS
Note 1 – Basis of Presentation
Accounting Policies
These interim statements of the Genmab group (Genmab or the Company) have been prepared in
accordance with IAS 34 as issued by the International Accounting Standards Board (IASB) and in
accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim
reports of listed companies. The interim report has not been reviewed or audited by Genmab’s external
auditors.
The interim report has been prepared using the same accounting policies as outlined in Section 1 – Basis
of Presentation in the financial statements in the Genmab 2021 Annual Report (Annual Report). A
number of new or amended standards became applicable for the current reporting period. Genmab was
not required to change its accounting policies as a result of adopting these standards. These interim
financial statements should be read in conjunction with the Annual Report.
Management Judgements and Estimates under IFRS
In preparing interim reports, certain provisions under IFRS require management to make judgements
(various accounting estimates and assumptions), which may significantly impact the group’s financial
statements. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual
Report.
Information about Geographical Areas
Genmab is managed and operated as one business unit, which is reflected in the organizational structure
and internal reporting. No separate lines of business or separate business entities have been identified
with respect to any licensed products, product candidates or geographical markets and no segment
information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further
details.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 27/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Note 2 – Revenue
The table below summarizes Genmab’s revenue by type and collaboration partner, and royalties by
product, under Genmab’s agreements.
Three Months Ended
Nine Months Ended
September 30,
September 30,
2022
2021
2022
2021
(DKK million)
Revenue by type:
Royalties
3,480
2,103
8,207
4,698
Reimbursement revenue
307
144
594
371
Milestone revenue
112
63
288
794
Collaboration revenue
182
—
273
—
License revenue
6
—
6
—
Total
4,087
2,310
9,368
5,863
Revenue by collaboration partner:
Janssen
3,172
1,876
7,378
4,722
AbbVie
—
—
—
245
Roche
207
222
597
384
Novartis
234
68
539
141
BioNTech
280
113
511
284
Seagen
192
31
330
87
Other
2
—
13
—
Total
4,087
2,310
9,368
5,863
Royalties by product:
DARZALEX
3,049
1,807
7,073
4,167
TEPEZZA
207
222
597
384
Kesimpta
213
68
509
140
Other
11
6
28
7
Total
3,480
2,103
8,207
4,698
In September 2020, Genmab commenced binding arbitration of two matters arising under its license
agreement with Janssen relating to daratumumab. Under the license agreement, Genmab is, among
other things, entitled to royalties from Janssen on net sales of daratumumab (marketed as DARZALEX for
IV administration and as DARZALEX FASPRO in the United States and as DARZALEX SC in Europe for
SC administration). In April 2022, the arbitral tribunal issued an award in the binding arbitration of the two
matters. Genmab did not seek a review of the award, and the award is now final.
Deferred Revenue
As part of the continued evaluation of deferred revenue related to the AbbVie Agreement, during the third
quarter of 2022, Genmab’s classification of deferred revenue reflects the current estimate of co-
development activities as of September 30, 2022. These co-development activities are related to a
performance obligation in connection with the product concepts under a research option agreement.
Refer to Note 2.1 in the Annual Report for further details regarding revenue.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 28/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Note 3 – Financial Instruments
Genmab’s portfolio is spread over a number of different securities with a focus on liquidity and the
preservation of capital. Genmab’s marketable securities in USD, DKK, EUR, and GBP as a percentage of
total marketable securities was as follows:
September 30,
December 31,
2022
2021
Percent
USD
82
%
75
%
DKK
11
%
16
%
EUR
6
%
8
%
GBP
1
%
1
%
Total
100
%
100
%
As of September 30, 2022, 74% of Genmab’s marketable securities were long-term A rated or higher, or
short-term A-1 / P-1 rated by S&P, Moody’s or Fitch compared to 68% as of December 31, 2021.
The table below shows the fair value measurements by level for Genmab’s financial assets measured at
fair value through profit or loss:
(DKK million)
September 30, 2022
December 31, 2021
Assets Measured at Fair Value
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
Total
Marketable securities
13,411
—
—
13,411
10,381
—
—
10,381
Other investments
94
—
61
155
344
—
27
371
Marketable Securities
All fair values are determined by reference to external sources using unadjusted quoted prices in
established markets for Genmab’s marketable securities (Level 1).
Other Investments
Other investments as of September 30, 2022 consist primarily of a DKK 85 million investment in common
shares of CureVac, compared to DKK 318 million as of December 31, 2021.
The investment in CureVac is recorded at fair value through profit or loss. The fair value of Genmab’s
investment in CureVac is determined using unadjusted quoted prices in established markets (Level 1).
Refer to Note 4.3 and Note 4.4 in the Annual Report for further details regarding Genmab’s marketable
securities and other investments.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 29/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Note 4 – Financial Income and Expenses
Three Months Ended
Nine Months Ended
September 30,
September 30,
2022
2021
2022
2021
(DKK million)
Financial income:
Interest and other financial income
97
35
184
162
Foreign exchange rate gain, net
1,456
476
3,248
1,049
Total financial income
1,553
511
3,432
1,211
Financial expenses:
Interest and other financial expenses
(6)
(4)
(16)
(10)
Loss on marketable securities, net
(140)
(50)
(455)
(184)
Loss on other investments, net
(66)
(176)
(280)
(209)
Total financial expenses
(212)
(230)
(751)
(403)
Net financial items
1,341
281
2,681
808
Foreign exchange rate gain, net was DKK 3,248 million in the first nine months of 2022 compared to DKK
1,049 million in the first nine months of 2021. The USD strengthened against the DKK in each period
which positively impacted our USD denominated marketable securities and cash holdings, but to a
greater extent in 2022. Refer to Note 4.2 in the Annual Report for further details regarding foreign
currency risk.
Loss on marketable securities, net was DKK 455 million in the first nine months of 2022 compared to DKK
184 million in the first nine months of 2021. The increase in fair value losses on marketable securities was
primarily driven by increases in interest rates in the United States and Europe.
Loss on other investments, net was DKK 280 million in the first nine months of 2022 compared to DKK
209 million in the first nine months of 2021. The change was primarily driven by the decrease in fair value
of Genmab’s investment in common shares of CureVac.
Note 5 – Share-Based Instruments
Restricted Stock Unit Program
Genmab A/S established RSU programs as an incentive for all Genmab employees, members of the
registered Executive Management, and members of the Board of Directors.
Nine Months Ended
September 30,
2022
2021
RSUs granted
260,523
159,567
Weighted average fair value per RSU granted (DKK)
2,209.10
2,149.55
RSUs vested
87,213
54,188
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 30/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Refer to Note 4.6 in the Annual Report for details on the RSU programs.
Warrant Program
Genmab A/S established warrant programs as an incentive for all Genmab employees, and members of
the registered Executive Management.
Nine Months Ended
September 30,
2022
2021
Warrants granted
249,901
147,568
Weighted average exercise price per warrant granted (DKK)
2,210.60
2,189.21
Weighted average Black-Scholes fair value per warrant granted (DKK)
647.44
683.79
Warrants exercised
110,826
139,305
Weighted average exercise price on date of grant per warrant exercised (DKK)
1,014.66
731.29
% change in share capital - warrants exercised
0.17%
0.21%
Refer to Note 4.6 in the Annual Report for details on the warrant programs.
Share-based compensation expense
Share-based compensation expenses related to Genmab RSU and warrant programs for the first
nine months of 2022 was DKK 326 million compared to DKK 228 million for the first nine months
of 2021.
Share repurchases
In general and under current authorizations, Genmab intends to purchase its own shares primarily to
honor obligations in relation to the share-based remuneration programs and mitigate the dilution effect of
share capital increases resulting from exercises of warrants.
As of September 30, 2022, Genmab’s 2021 authorization has shares available for repurchase, while
Genmab’s 2019 authorization has been fully used. The 2016 authorization expired in March 2021.
2021
Authorization
2019
Authorization
2016
Authorization
Number of shares authorized for repurchase
1
500,000
500,000
500,000
Actual shares repurchased under authorization
40,000
500,000
255,000
Shares available for repurchase as of September 30, 2022
460,000
—
—
1
Nominal value of DKK 500,000
As announced on June 17, 2022, Genmab initiated a share buy-back program. During the first nine
months of 2022, Genmab acquired 370,000 of its own shares, representing approximately 0.6% of share
capital as of December 31, 2021. The total amount paid to acquire the shares, including directly
attributable costs, was DKK 908 million and was recognized as a deduction to shareholders’ equity.
During the first nine months of 2021, Genmab acquired 200,000 of its own shares, representing
approximately 0.3% of share capital as of December 31, 2020. The total amount paid to acquire the
shares, including directly attributable costs, was DKK 447 million and was recognized as a deduction to
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 31/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
shareholders’ equity. These shares are classified as treasury shares and are presented within retained
earnings on the balance sheet as of September 30, 2022.
As of September 30, 2022, 599,883 treasury shares were held by Genmab to cover obligations in relation
to the RSU programs and to mitigate the dilutive effect of share capital increases resulting from future
exercises of warrants.
Note 6 – Related Parties
Genmab’s related parties are Genmab A/S’ (parent company) subsidiaries, Board of Directors, the
registered Executive Management, and close members of the family of these persons.
Genmab has not granted any loans, guarantees or other commitments to or on behalf of any of the
members of the Board of Directors or members of the registered Executive Management.
Other than the remuneration and other transactions relating to the Board of Directors and the registered
Executive Management described in Note 5.1 in the Annual Report, there were no material related party
transactions during the first nine months of 2022.
Changes to the Executive Management Team and the Board of Directors
Genmab has decided to implement an administrative organizational change whereby effective January 1,
2023, only Jan van de Winkel, President and Chief Executive Officer, and Anthony Pagano, Executive
Vice President and Chief Financial Officer, will be formally registered as executive managers with the
Danish Business Authority. Judith Klimovsky, Executive Vice President and Chief Development Officer,
Anthony Mancini, Executive Vice President and Chief Operating Officer, and Tahamtan Ahmadi,
Executive Vice President and Chief Medical Officer, will cease to be registered as executive managers
with the Danish Business Authority; however, apart from the formal registration amendments there will be
no changes to the Executive Management Team, including titles, areas of responsibility or otherwise.
Additionally, during the first nine months of 2022, there were two changes to the Executive Management
Team. Effective March 1, 2022, Chris Cozic was appointed Executive Vice President and Chief People
Officer, and Birgitte Stephensen was appointed Executive Vice President and Chief Legal Officer. They
join the existing Executive Management Team but are not regarded as executive managers pursuant to
the Danish Companies Act and are therefore not registered with the Danish Business Authority.
Following Genmab A/S’ Annual General Meeting on March 29, 2022, the Board of Directors is comprised
of five independent board members, one non-independent board member, and three employee-elected
board members. Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo
Paoletti, and Dr. Anders Gersel Pedersen were re-elected to the Board of Directors for a one-year period.
Elizabeth O’Farrell was newly elected for a one-year period. Mijke Zachariasse, Martin Schultz and
Takahiro Hamatani were elected to the Board of Directors by the employees for a three-year period. Peter
Storm Kristensen and Rima Bawarshi Nassar stepped down from the Board of Directors.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 32/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Note 7 – Leases
Amounts recognized in the balance sheet
The balance sheet shows the following amounts relating to leases:
September 30,
December 31,
2022
2021
(DKK million)
Right-of-use assets
Properties
547
352
Equipment
1
2
Total right-of-use assets
548
354
Lease liabilities
Current
79
62
Non-current
550
363
Total lease liabilities
629
425
During the first nine months of 2022, there were additions to Genmab’s right-of-use assets and lease
liabilities related to the commencement of leases in the Netherlands with respect to office and laboratory
space. During the first nine months of 2021, there were additions to Genmab’s right-of-use assets and
lease liabilities related to the commencement of leases in Japan and the United States with respect to
office space.
Significant leases not yet commenced
During 2020, Genmab entered into a lease agreement with respect to the new headquarters in Denmark
with a commencement date in March 2023 and is non-cancellable until March 2038. The total future
minimum payments over the term of the lease are approximately DKK 339 million and estimated capital
expenditures to fit out the space are approximately DKK 128 million.
Amounts recognized in the statement of comprehensive income
The statement of comprehensive income shows the following amounts relating to leases:
Three Months Ended
Nine Months Ended
September 30,
September 30,
2022
2021
2022
2021
(DKK million)
Depreciation charge of right-of-use assets
Properties
22
14
52
39
Equipment
—
—
1
1
Total depreciation charge of right-of-use assets
22
14
53
40
Interest expense
4
3
11
9
Expense relating to short-term leases
—
—
—
1
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 33/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
Interest expense is included in net financial items and expenses relating to short-term leases are included
in operating expenses in the statement of comprehensive income.
Note 8 - Subsequent Events to the Balance Sheet Date
No events have occurred subsequent to the balance sheet date that could significantly affect the financial
statements as of September 30, 2022.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 34/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
ABOUT GENMAB
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years,
Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation
antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that
make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with
biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune
checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo,
Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab
.
This Interim Report contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar
expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of
our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract
and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a
further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available
on www.genmab.com
and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Interim Report nor to confirm such statements to reflect subsequent events or circumstances after
the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab
®
; the Y-shaped Genmab logo
®
; Genmab in combination
with the
Y-shaped Genmab logo
®
; HuMax®; DuoBody
®
; DuoBody in combination with the DuoBody logo
®
; HexaBody
®
; HexaBody in
combination with the HexaBody logo
®
; DuoHexaBody
®
; and HexElect
®
. Tivdak
®
is a trademark of Seagen Inc.; EPCORE™ is a
trademark of AbbVie Biotechnology Ltd.;
Kesimpta
®
and Sensoready
®
are trademarks of Novartis AG or its affiliates; DARZALEX
®
,
DARZALEX FASPRO
®
RYBREVANT
®
and TECVAYLI
®
are trademarks of Johnson & Johnson; TEPEZZA
®
is a trademark of Horizon
Therapeutics Ireland DAC.
Interim Report for the First Nine Months of 2022
Genmab A/S
Tel: +45 7020 2728
Company Announcement no. 55
Kalvebod Brygge 43
Fax: +45 7020 2729
Page 35/35
1560 Copenhagen V, Denmark
www.genmab.com
CVR no. 2102 3884
DIRECTORS’ AND MANAGEMENT’S STATEMENT ON THE INTERIM REPORT
The Board of Directors and the registered members of Executive Management have today
considered and adopted the unaudited interim report of the Genmab group for the nine months
ended September 30, 2022.
The interim report is prepared in accordance with IAS 34, “Interim Financial Reporting,” as issued
by the IASB and in accordance with IAS 34 as endorsed by the EU, and additional Danish
disclosure requirements for interim reports of listed companies.
We consider the applied accounting policies to be appropriate and, in our opinion, the interim
report gives a true and fair view of the assets and liabilities, financial position, results of operation
and cash flows of the group.
Furthermore, we consider the Management’s Review to give a true and fair account of the
development in the group’s activities and financial affairs, results of operations and the group’s
financial position as a whole as well as a description of the significant risks and uncertainties
which the group faces, as further described in our 2021 Annual Report and the Form 20-F filed
with the U.S. Securities and Exchange Commission in February 2022.
Copenhagen, November 9, 2022
Registered Members of Executive Management
Jan van de Winkel
Anthony Pagano
Judith Klimovsky
Anthony Mancini
Tahamtan Ahmadi
(President & CEO)
(Executive Vice
President & CFO)
(Executive Vice
President & CDO)
(Executive Vice
President & COO)
(Executive Vice
President & CMO)
Board of Directors
Deirdre P. Connelly
Pernille Erenbjerg
Anders Gersel Pedersen
(Chair)
(Deputy Chair)
Rolf Hoffmann
Paolo Paoletti
Elizabeth O’Farrell
Mijke Zachariasse
Takahiro Hamatani
Martin Schultz
(Employee elected)
(Employee elected)
(Employee elected)
Interim report (other than 6 months)No audit assistanceParsePort XBRL Converter2022-01-012022-09-302021-01-012021-09-302022-11-10529900MTJPDPE4MHJ122Reporting class D21023884Copenhagen2022-11-0925578198KPMG P/SDampfærgevej 282100 København Ø529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember529900MTJPDPE4MHJ1222022-07-012022-09-30529900MTJPDPE4MHJ1222021-07-012021-09-30529900MTJPDPE4MHJ1222022-01-012022-09-30529900MTJPDPE4MHJ1222021-01-012021-09-30529900MTJPDPE4MHJ1222022-09-30529900MTJPDPE4MHJ1222021-12-31529900MTJPDPE4MHJ1222020-12-31529900MTJPDPE4MHJ1222021-09-30529900MTJPDPE4MHJ1222020-12-31ifrs-full:IssuedCapitalMember529900MTJPDPE4MHJ1222021-01-012021-09-30ifrs-full:IssuedCapitalMember529900MTJPDPE4MHJ1222021-09-30ifrs-full:IssuedCapitalMember529900MTJPDPE4MHJ1222020-12-31ifrs-full:SharePremiumMember529900MTJPDPE4MHJ1222021-01-012021-09-30ifrs-full:SharePremiumMember529900MTJPDPE4MHJ1222021-09-30ifrs-full:SharePremiumMember529900MTJPDPE4MHJ1222020-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900MTJPDPE4MHJ1222021-01-012021-09-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900MTJPDPE4MHJ1222021-09-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900MTJPDPE4MHJ1222020-12-31ifrs-full:RetainedEarningsMember529900MTJPDPE4MHJ1222021-01-012021-09-30ifrs-full:RetainedEarningsMember529900MTJPDPE4MHJ1222021-09-30ifrs-full:RetainedEarningsMember529900MTJPDPE4MHJ1222021-12-31ifrs-full:IssuedCapitalMember529900MTJPDPE4MHJ1222022-01-012022-09-30ifrs-full:IssuedCapitalMember529900MTJPDPE4MHJ1222022-09-30ifrs-full:IssuedCapitalMember529900MTJPDPE4MHJ1222021-12-31ifrs-full:SharePremiumMember529900MTJPDPE4MHJ1222022-01-012022-09-30ifrs-full:SharePremiumMember529900MTJPDPE4MHJ1222022-09-30ifrs-full:SharePremiumMember529900MTJPDPE4MHJ1222021-12-31ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900MTJPDPE4MHJ1222022-01-012022-09-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900MTJPDPE4MHJ1222022-09-30ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember529900MTJPDPE4MHJ1222021-12-31ifrs-full:RetainedEarningsMember529900MTJPDPE4MHJ1222022-01-012022-09-30ifrs-full:RetainedEarningsMember529900MTJPDPE4MHJ1222022-09-30ifrs-full:RetainedEarningsMember529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember1529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember2529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember3529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember4529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember5529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember1529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember2529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember3529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember4529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember5529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember6529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember7529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember8529900MTJPDPE4MHJ1222022-01-012022-09-30cmn:ConsolidatedMember9iso4217:DKKiso4217:DKKxbrli:shares